ライフサイエンスコーパス: nicotinic antagonist

1 s were worsened by mecamylamine, a selective nicotinic antagonist.

2 ioning was attenuated by coadministration of nicotinic antagonist.

3 arinic antagonist and weakly attenuated by a nicotinic antagonist.

4 unctions and adenosine receptors, but not by nicotinic antagonists.

5 quency during inspiration was not altered by nicotinic antagonists.

6 or nicotinic agonists and lower affinity for nicotinic antagonists.

7 carinic or glutamate antagonists, but not by nicotinic antagonists.

8 onists, p = 0.01) for several noncompetitive nicotinic antagonists.

9 alpha-Conotoxins are two-disulfide-bridged nicotinic antagonists, 13-19 amino acids in length; kapp

10 s bisindolylmaleimide IV and V have far less nicotinic antagonist activity (IC(50) >1 microM); the ac

11 less frequent waves that could be blocked by nicotinic antagonists and had a characteristic postwave

12 g) and dihydro-beta-erythroidine (2 mg/kg) - nicotinic antagonists - and atropine (2 mg/kg) - a musca

13 maleimides I through III are the most potent nicotinic antagonists at the nicotinic cholinergic recep

14 ion was also inhibited by the muscarinic and nicotinic antagonists atropine and mecamylamine, respect

15 Intrastriatally, the nicotinic antagonists blocked induction but not expressi

16 age of postnatal day 1 (P1) were blocked by nicotinic antagonists, but not by muscarinic or glutamat

17 In a dose-dependent fashion, the nicotinic antagonist catestatin blocked agonist desensit

18 Peptide nicotinic antagonists (catestatins, substance P) were fa

19 ion, making it the most neuronally selective nicotinic antagonist characterized thus far.

20 The nicotinic antagonists curare and dihydro-beta-erythroidi

21 blocked by the simultaneous addition of the nicotinic antagonist d-tubocurarine.

22 A nicotinic antagonist, d-tubocurarine chloride, completel

23 als, the inhibitory effect of muscarinic and nicotinic antagonists did not differ significantly.

24 Further addition of the nicotinic antagonist dihydro-beta-erythroidine (DHbetaE)

25 Focal application of the nicotinic antagonist dihydro-beta-erythroidine in an alp

26 educed in number or entirely absent when the nicotinic antagonist dihydro-beta-erythroidine was prese

27 antagonist atropine (0.1 microM), not by two nicotinic antagonists, dihydro-beta-erythroidine (10 mic

28 Both muscarinic and nicotinic antagonists dose-dependently attenuated clonid

29 However, nicotinic antagonists, except hexamethonium, have compar

30 In comparison to other nicotinic antagonists from Conus venoms, alphaS-RVIIIA e

31 alpha-Bungarotoxin, the classic nicotinic antagonist, has high specificity for muscle ty

32 Nicotinic antagonists have different effects on hair-cel

33 The nicotinic antagonists, however, blocked both the inducti

34 nists have been shown to improve memory, and nicotinic antagonists impair it.

35 The rank order of potency of nicotinic antagonists in blocking the function of this a

36 irmed by blockade of the EPSPs or EPSCs with nicotinic antagonists, including DHbetaE, D-tubocurare,

37 e of the most potent noncompetitive neuronal nicotinic antagonists, indeed the most potent such antag

38 oxin MII, which is also a potent alpha3beta2 nicotinic antagonist, it is much less hydrophobic, and t

39 erent from the many conopeptides shown to be nicotinic antagonists; it is most similar in its general

40 of two sessions 2 hours after receiving the nicotinic antagonist mecamylamine (10 mg) or placebo ora

41 BAergic antagonists, but were blocked by the nicotinic antagonist mecamylamine (MEC).

42 Such responses were blocked by the nicotinic antagonist mecamylamine but not by the muscari

43 reduced attentional modulation, whereas the nicotinic antagonist mecamylamine had no systematic effe

44 ate antagonist kynurenic acid (KYNA) and the nicotinic antagonist mecamylamine hydrochloride (MCM) re

45 ted withdrawal by systemically injecting the nicotinic antagonist mecamylamine in mice chronically tr

46 nist methyllycaconitine or the non-selective nicotinic antagonist mecamylamine indicated that the eff

47 r chronic in ovo treatment with the neuronal nicotinic antagonist mecamylamine or the GABA receptor a

48 The nicotinic antagonist mecamylamine, 3 mg/kg, induced a sm

49 as abolished in the presence of the specific nicotinic antagonist mecamylamine, indicating that it wa

50 d by nicotine withdrawal precipitated by the nicotinic antagonist mecamylamine.

51 Nicotinic antagonists mecamylamine and dihydro-beta-eryt

52 When treated with an acute dose of the nicotinic antagonist, mecamylamine (0.5 mg/kg, sc), the

53 Pretreatment with the centrally acting nicotinic antagonist, mecamylamine (1 mg/kg), blocked ni

54 ne were blocked by pretreating rats with the nicotinic antagonist, mecamylamine.

55 Local infusion of the nicotinic antagonist methyllycaconitine (MLA) to block a

56 Furthermore, coaddition of either the nicotinic antagonist methyllycaconitine citrate hydrate

57 ckade of this effect with either the alpha-7 nicotinic antagonist methyllycaconitine or the non-selec

58 Here, we report that the alpha7-selective nicotinic antagonist, methyllycaconitine (MLA), protects

59 inic agonists, epibatidine and lobeline, and nicotinic antagonists, methyllycaconitine, alpha-bungaro

60 n a manner that was in turn blocked with the nicotinic antagonist methyllyconitine (1 microM).

61 In mouse striatal slices, nicotinic antagonists or depletion of endogenous acetylc

62 These nicotinic antagonist peptides from Conus are broadly div

63 dence indicated that each variant acted as a nicotinic antagonist: potency to inhibit secretion paral

64 In chicks, nicotinic antagonists such as alpha-bungarotoxin (alphaB

65 ype (thereby causing paralysis) and a second nicotinic antagonist targeted to the alpha3beta2 nAChR s

66 ging pattern in venomous predators, with one nicotinic antagonist targeted to the muscle subtype (the

67 hus, alphaS-RVIIIA defines a novel family of nicotinic antagonists within the S superfamily.